| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | 0.12 | 0.6 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | 0.031 | 0.6 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |